- Home
- UNCY vs QNCX Comparison
UNCY vs QNCX Comparison
Compare UNCY & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- QNCX
- Stock Information
- Founded
- UNCY 2016
- QNCX 2012
- Country
- UNCY United States
- QNCX United States
- Employees
- UNCY N/A
- QNCX N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNCY Health Care
- QNCX Health Care
- Exchange
- UNCY Nasdaq
- QNCX Nasdaq
- Market Cap
- UNCY 58.7M
- QNCX 62.0M
- IPO Year
- UNCY 2021
- QNCX 2019
- Fundamental
- Price
- UNCY $0.55
- QNCX $1.27
- Analyst Decision
- UNCY Strong Buy
- QNCX Strong Buy
- Analyst Count
- UNCY 3
- QNCX 5
- Target Price
- UNCY $6.50
- QNCX $8.00
- AVG Volume (30 Days)
- UNCY 925.3K
- QNCX 126.8K
- Earning Date
- UNCY 05-12-2025
- QNCX 05-12-2025
- Dividend Yield
- UNCY N/A
- QNCX N/A
- EPS Growth
- UNCY N/A
- QNCX N/A
- EPS
- UNCY N/A
- QNCX N/A
- Revenue
- UNCY N/A
- QNCX N/A
- Revenue This Year
- UNCY N/A
- QNCX N/A
- Revenue Next Year
- UNCY $888.72
- QNCX N/A
- P/E Ratio
- UNCY N/A
- QNCX N/A
- Revenue Growth
- UNCY N/A
- QNCX N/A
- 52 Week Low
- UNCY $0.20
- QNCX $0.51
- 52 Week High
- UNCY $1.60
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- UNCY 40.61
- QNCX 36.91
- Support Level
- UNCY $0.60
- QNCX $1.30
- Resistance Level
- UNCY $0.65
- QNCX $1.42
- Average True Range (ATR)
- UNCY 0.05
- QNCX 0.09
- MACD
- UNCY -0.01
- QNCX -0.00
- Stochastic Oscillator
- UNCY 3.86
- QNCX 4.17
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.